Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rbv-Gzr'

Rbv-Gzr published presentations and documents on DocSlides.

Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
by badra
Duke University School of Medicine. Durham, North ...
How to optimize treatment of G1 patients?
How to optimize treatment of G1 patients?
by KissesForYou
Prof. G. K. K. Lau 2012. Standard of care (SOC) ...
NS5A and polymerase inhibitors
NS5A and polymerase inhibitors
by LoveBug
Mark Sulkowski, MD. Professor of Medicine. Johns H...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
M.W. Fried , 1 M. Buti,
M.W. Fried , 1 M. Buti,
by iamamercy
2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by webraph
Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
Hepatitis C Imtiaz Alam, M.D.
Hepatitis C Imtiaz Alam, M.D.
by olivia-moreira
Medical Director, Austin Hepatitis Center. 1. Hep...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
Prevention strategies for HIV/HCV co infection
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...
Chronic hepatitis C: guidelines for screening and
Chronic hepatitis C: guidelines for screening and
by aaron
treatment. Lisa M. Glass, MD. Clinical Lecturer. ...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by lois-ondreau
Sameh W. Boktor, MD, MPH. Medical Epidemiologist....
OBV/PTV/r DSV Open label
OBV/PTV/r DSV Open label
by kittie-lecroy
≥ 18 years. Chronic HCV infection. Genotype 1. ...
OBV/PTV/r DSV RBV OBV/PTV/r
OBV/PTV/r DSV RBV OBV/PTV/r
by ellena-manuel
DSV . placebo. Randomisation*. Partial blind. 1...
Peginterferon alfa-2a +
Peginterferon alfa-2a +
by stefany-barnette
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...
Forns
Forns
by ellena-manuel
X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE ...
SOF/VEL + RBV
SOF/VEL + RBV
by celsa-spraggs
N = 69. >. 18 years. Failure to SOF/VEL . or ...
SMV 12W + PEG-IFN + RBV 24-48W **
SMV 12W + PEG-IFN + RBV 24-48W **
by alexa-scheidler
SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation ...
SAPPHIRE-I
SAPPHIRE-I
by ellena-manuel
Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...
Ombitasvir-
Ombitasvir-
by kittie-lecroy
Paritaprevir. -. Ritonavir. . and . Dasabuvir. ...
Dore G. J
Dore G. J
by myesha-ticknor
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
PEG alfa-2a +
PEG alfa-2a +
by tawny-fly
RBV . versus. . PEG alfa-. 2a . versus. INF + R...
TURQUOISE-I
TURQUOISE-I
by marina-yarberry
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
Randomisation
Randomisation
by pamella-moone
*. 1:1. Open-label. ≥ 18 years. HCV genotype ...
Dore G. J
Dore G. J
by pasty-toler
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Hepatitis C Drug Pipeline
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...
Reddy KR. Lancet Infect Dis. 2015;15:27-35
Reddy KR. Lancet Infect Dis. 2015;15:27-35
by natalia-silvester
ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...
Design
Design
by test
PTV150/r + OBV + . DSV . + RBV. PTV150/r + . DSV...
State of the Art Therapy for HCV
State of the Art Therapy for HCV
by liane-varnes
Last Updated: February . 21, 2014. Robert G. Gish...
Direct Acting Antivirals: What are they? What is their pl
Direct Acting Antivirals: What are they? What is their pl
by tawny-fly
Mark Sulkowski, MD. Associate Professor of Medici...